Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study

Ann Oncol. 2019 Jan 1;30(1):13-16. doi: 10.1093/annonc/mdy473.

Authors

M Kok¹, E P Winer², S Loi³

Affiliations

¹ Departments of Medical Oncology, Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
³ Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.

PMID: 30351400
DOI: 10.1093/annonc/mdy473

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
B7-H1 Antigen*
Cohort Studies
Humans
Triple Negative Breast Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
pembrolizumab